Beigene Ltd
HKEX:6160

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
HKEX:6160
Watchlist
Price: 162.6 HKD -0.25% Market Closed
Market Cap: 221.6B HKD

EV/EBITDA
Enterprise Value to EBITDA

-86.7
Current
-13.1
Median
4.6
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-86.7
=
Enterprise Value
212.9B HKD
/
EBITDA
-2.2B CNY
EBITDA Growth EV/EBITDA to Growth
CN
Beigene Ltd
HKEX:6160
Average EV/EBITDA: 15.2
Negative Multiple: -86.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 934.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
13.8
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.7
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -697.8 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
111.7
2-Years Forward
EV/EBITDA
39.8
3-Years Forward
EV/EBITDA
21.8